New directions in the neoadjuvant treatment of HER2+ breast cancer

被引:1
|
作者
Hobbs, Evthokia A. [1 ]
Hurvitz, Sara A. [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, 2825 Santa Monica Blvd,Suite 211, Santa Monica, CA 90404 USA
关键词
breast cancer; HER2; lapatinib; neoadjuvant; pathologic complete response; pertuzumab; PIK3CA; trastuzumab;
D O I
10.2217/BMT.15.12
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Approximately 20% of breast cancer demonstrates amplification of the HER2 gene resulting in overexpression of the HER2 protein on the cell surface. Effective targeting with anti-HER2 monoclonal antibodies (trastuzumab, pertuzumab, trastuzumab-emtansine) and tyrosine kinase inhibitors (lapatinib) dramatically improves the natural history of this aggressive disease. Patients with HER2-overexpressing breast cancer (HER2+) achieve higher rates of pathologic complete response (pCR) to cytotoxic chemotherapy and HER2-targeted therapy in neoadjuvant trials compared with less aggressive subtypes. Moreover, a trend toward a positive correlation between pCR and improved long-term survival appears to be emerging in neoadjuvant clinical trials. This article reviews the various definitions of pCR as an end point in neoadjuvant clinical trials and summarizes the use of anti-HER2-targeted agents in the neoadjuvant setting for HER2+ disease.
引用
收藏
页码:223 / 234
页数:12
相关论文
共 50 条
  • [1] Pertuzumab in the Treatment of HER2+ Breast Cancer
    Jhaveri, Komal
    Esteva, Francisco J.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (04): : 591 - 598
  • [2] Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
    Nicola Cosgrove
    Alex J. Eustace
    Peter O’Donovan
    Stephen F. Madden
    Bruce Moran
    John Crown
    Brian Moulton
    Patrick G. Morris
    Liam Grogan
    Oscar Breathnach
    Colm Power
    Michael Allen
    Janice M. Walshe
    Arnold D. Hill
    Anna Blümel
    Darren O’Connor
    Sudipto Das
    Małgorzata Milewska
    Joanna Fay
    Elaine Kay
    Sinead Toomey
    Bryan T. Hennessy
    Simon J. Furney
    [J]. npj Breast Cancer, 9
  • [3] Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
    Cosgrove, Nicola
    Eustace, Alex J.
    O'Donovan, Peter
    Madden, Stephen F.
    Moran, Bruce
    Crown, John
    Moulton, Brian
    Morris, Patrick G.
    Grogan, Liam
    Breathnach, Oscar
    Power, Colm
    Allen, Michael
    Walshe, Janice M.
    Hill, Arnold D.
    Blumel, Anna
    O'Connor, Darren
    Das, Sudipto
    Milewska, Malgorzata
    Fay, Joanna
    Kay, Elaine
    Toomey, Sinead
    Hennessy, Bryan T.
    Furney, Simon J.
    [J]. NPJ BREAST CANCER, 2023, 9 (01)
  • [4] ADDING PERTUZUMAB IN NEOADJUVANT TREATMENT OF PATIENTS WITH HER2+ BREAST CANCER IN SPAIN: A COST OFFSETS STUDY
    Albanell, J.
    Ciruelos, E.
    Colomer, R.
    De la Haba, J.
    Martin, M.
    De Salas-Cansado, M.
    Munoz-Molina, B.
    Tournier, C.
    Thuresson, P.
    Schleich, W.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2015, 117 : 42 - 42
  • [5] HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
    Guy Jerusalem
    Patrizio Lancellotti
    Sung-Bae Kim
    [J]. Breast Cancer Research and Treatment, 2019, 177 : 237 - 250
  • [6] Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer
    Fiúza M.
    [J]. Advances in Therapy, 2009, 26 (Suppl 1) : S9 - S17
  • [7] Treatment of brain metastases in patients with HER2+ breast cancer
    Bravo Marques J.M.
    [J]. Advances in Therapy, 2009, 26 (Suppl 1) : S18 - S26
  • [8] The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data
    Andreia Borges
    Filipa Pereira
    Patrícia Redondo
    Luís Antunes
    Cláudia Vieira
    Pedro Antunes
    Maria José Bento
    Susana Sousa
    José Machado Lopes
    Francisco Rocha-Gonçalves
    Joaquim Abreu de Sousa
    Deolinda Sousa Pereira
    Marina Borges
    [J]. Health Economics Review, 11
  • [9] Adjuvant therapy of HER2+ breast cancer
    EP Winer
    [J]. Breast Cancer Research, 11
  • [10] Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
    Rupert Bartsch
    Simon Peter Gampenrieder
    Gabriel Rinnerthaler
    Edgar Petru
    Daniel Egle
    Andreas Petzer
    Marija Balic
    Ursula Pluschnig
    Thamer Sliwa
    Christian Singer
    [J]. Wiener klinische Wochenschrift, 2022, 134 : 63 - 72